We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

80 hedge funds and large institutions have $123M invested in Crescent Biopharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,004% more call options, than puts

Call options by funds: $2.9M | Put options by funds: $263K

0.09% less ownership

Funds ownership: 0.93% → 0.84% (-0.09%)

8% less funds holding

Funds holding: 87 → 80 (-7)

19% less capital invested

Capital invested by funds: $152M → $123M (-$29.1M)

26% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 31

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
80
Holders Change
-7
Holders Change %
-8.05%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
31
Closed
13
Calls
$2.9M
Puts
$263K
Net Calls
+$2.64M
Net Calls Change
+$2.47M

Top Buyers

1
EC
EcoR1 Capital
California
+$7.02M
2
N
Nuveen
North Carolina
+$725K
3
Bank of America
Bank of America
North Carolina
+$709K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$631K
5
CM
Caption Management
Oklahoma
+$570K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.37M
2
CCM
Camber Capital Management
Massachusetts
-$1.91M
3
Morgan Stanley
Morgan Stanley
New York
-$1.37M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.25M
5
BCM
Bridgeway Capital Management
Texas
-$691K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
26
ClariVest Asset Management
California
$405K -$31.3K -82 -6%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$397K +$11.5K +30 +2%
Citadel Advisors
28
Citadel Advisors
Florida
$360K -$549K -1,437 -55%
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$347K +$73.4K +192 +20%
SFI
30
Susquehanna Fundamental Investments
Pennsylvania
$288K +$318K +833 +786%
Charles Schwab
31
Charles Schwab
California
$270K -$1.91K -5 -0.6%
Goldman Sachs
32
Goldman Sachs
New York
$269K -$45.5K -119 -12%
JP Morgan Chase
33
JP Morgan Chase
New York
$233K -$73.4K -192 -20%
AllianceBernstein
34
AllianceBernstein
Tennessee
$223K -$9.94K -26 -3%
PPA
35
Parametric Portfolio Associates
Washington
$212K -$7.64K -20 -3%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$193K +$122K +320 +104%
DCM
37
Dupont Capital Management
Delaware
$190K +$237K +619 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$168K +$5.73K +15 +3%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$166K – – –
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$162K -$23.3K -61 -10%
Wells Fargo
41
Wells Fargo
California
$155K -$590K -1,543 -75%
AQR Capital Management
42
AQR Capital Management
Connecticut
$150K +$2.68K +7 +1%
AC
43
Athanor Capital
New York
$147K -$89.8K -235 -33%
Group One Trading
44
Group One Trading
Illinois
$136K +$169K +443 New
UBS Group
45
UBS Group
Switzerland
$132K -$43.2K -113 -21%
TRCT
46
Tower Research Capital (TRC)
New York
$125K +$127K +332 +449%
Invesco
47
Invesco
Georgia
$117K -$4.21K -11 -3%
Arrowstreet Capital
48
Arrowstreet Capital
Massachusetts
$108K -$189K -494 -58%
Squarepoint
49
Squarepoint
New York
$98K -$68K -178 -36%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$89K – – –
1
2
3 4

CBIO Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2020, worth a combined $123M — down 19% from $152M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CBIO and 7 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 23 added.

The largest buyer was EcoR1 Capital, adding an estimated $7.02M. The largest seller was Wellington Management Group, cutting an estimated $3.37M.

  • 80 institutional investors held Crescent Biopharma (CBIO) as of Q3 2020, down from 87 in Q2 2020.
  • Funds reported $123M of Crescent Biopharma stock for Q3 2020, down 19% quarter-over-quarter.
  • 7 funds opened new Crescent Biopharma positions in Q3 2020 and 13 closed out, a net change of -6 holders.
  • The largest Crescent Biopharma buyer in Q3 2020 was EcoR1 Capital, an estimated $7.02M added.
  • The largest Crescent Biopharma seller in Q3 2020 was Wellington Management Group, an estimated $3.37M sold.

Based on aggregated 13F filings for Q3 2020.